Adrian Bloor

6.2k total citations
67 papers, 1.4k citations indexed

About

Adrian Bloor is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Adrian Bloor has authored 67 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Genetics, 32 papers in Pathology and Forensic Medicine and 24 papers in Hematology. Recurrent topics in Adrian Bloor's work include Lymphoma Diagnosis and Treatment (32 papers), Chronic Lymphocytic Leukemia Research (28 papers) and Hematopoietic Stem Cell Transplantation (13 papers). Adrian Bloor is often cited by papers focused on Lymphoma Diagnosis and Treatment (32 papers), Chronic Lymphocytic Leukemia Research (28 papers) and Hematopoietic Stem Cell Transplantation (13 papers). Adrian Bloor collaborates with scholars based in United Kingdom, Germany and France. Adrian Bloor's co-authors include Kirsty Thomson, Karl S. Peggs, Ronjon Chakraverty, Stephen Mackinnon, David C. Linch, Gordon Cook, James E. Griffin, Rohini Radia, David T Yeung and Kilian Kelly and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Adrian Bloor

60 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adrian Bloor United Kingdom 19 651 598 482 442 311 67 1.4k
Majid Kazmi United Kingdom 19 234 0.4× 454 0.8× 424 0.9× 568 1.3× 279 0.9× 39 1.4k
Manuela Badoglio France 19 215 0.3× 529 0.9× 327 0.7× 389 0.9× 308 1.0× 51 1.2k
Massimo Degan Italy 24 764 1.2× 900 1.5× 603 1.3× 239 0.5× 826 2.7× 67 1.9k
SC Jhanwar United States 14 408 0.6× 423 0.7× 459 1.0× 471 1.1× 418 1.3× 28 1.6k
RA Newman United States 7 647 1.0× 837 1.4× 572 1.2× 307 0.7× 735 2.4× 10 2.1k
HJ Sutherland Canada 15 465 0.7× 329 0.6× 568 1.2× 1.1k 2.6× 462 1.5× 19 1.9k
Jee Sook Hahn South Korea 19 222 0.3× 498 0.8× 531 1.1× 244 0.6× 161 0.5× 57 1.2k
Gianmaria Borleri Italy 22 467 0.7× 331 0.6× 1.1k 2.2× 523 1.2× 1.1k 3.5× 43 2.2k
JE Leonard United States 6 507 0.8× 729 1.2× 481 1.0× 235 0.5× 637 2.0× 10 1.8k
Marie Parrens France 25 553 0.8× 1.3k 2.2× 859 1.8× 248 0.6× 549 1.8× 95 2.5k

Countries citing papers authored by Adrian Bloor

Since Specialization
Citations

This map shows the geographic impact of Adrian Bloor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrian Bloor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrian Bloor more than expected).

Fields of papers citing papers by Adrian Bloor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adrian Bloor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrian Bloor. The network helps show where Adrian Bloor may publish in the future.

Co-authorship network of co-authors of Adrian Bloor

This figure shows the co-authorship network connecting the top 25 collaborators of Adrian Bloor. A scholar is included among the top collaborators of Adrian Bloor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adrian Bloor. Adrian Bloor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Walewska, Renata, Toby A. Eyre, Adrian Bloor, et al.. (2025). 2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia. British Journal of Haematology. 207(6). 2296–2313.
2.
3.
Renders, Simon, Hervé Finel, William Townsend, et al.. (2024). Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study. Blood Advances. 8(21). 5571–5578.
4.
Kelly, Kilian, et al.. (2024). Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease. Nature Medicine. 30(6). 1556–1558. 14 indexed citations
5.
Roddie, Claire, Lorna Neill, Wendy Osborne, et al.. (2023). Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Advances. 7(12). 2872–2883. 64 indexed citations
6.
Eyre, Toby A., Sally F. Barrington, Jessica Okosun, et al.. (2022). Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation. Haematologica. 108(3). 785–796. 3 indexed citations
7.
8.
Hillmen, Peter, Rebecca H. Boucher, Nichola Webster, et al.. (2020). Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. Blood. 136(Supplement 1). 17–18. 13 indexed citations
9.
Hillmen, Peter, Andy C. Rawstron, Kristian Brock, et al.. (2019). Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. Journal of Clinical Oncology. 37(30). 2722–2729. 180 indexed citations
10.
Bloor, Adrian, Amit Patel, James E. Griffin, et al.. (2018). A Phase I Trial of iPSC-Derived MSCs (CYP-001) in Steroid-Resistant Acute GvHD. Blood. 132(Supplement 1). 4562–4562. 5 indexed citations
11.
12.
13.
Hillmen, Peter, Andy C. Rawstron, Kristian Brock, et al.. (2017). The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of efficacy.. Haematologica. 102. 311–311. 4 indexed citations
14.
Howard, Dena, Talha Munir, Lucy McParland, et al.. (2017). Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials. 18(1). 387–387. 25 indexed citations
15.
Radford, John, Pam McKay, Ram Malladi, et al.. (2017). Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation. Bone Marrow Transplantation. 52(3). 452–454. 3 indexed citations
16.
Reyal, Yasmin, Irfan Kayani, Adrian Bloor, et al.. (2016). Impact of Pretransplantation 18F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell–Depleted Allogeneic Transplantation for Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 22(7). 1234–1241. 22 indexed citations
17.
Eyre, Toby A., Ruth Clifford, Adrian Bloor, et al.. (2015). SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER'S SYNDROME. Haematologica. 100. 109–109. 2 indexed citations
18.
Papageorgiou, Sotirios G., Anna Castleton, Adrian Bloor, & Panagiotis Kottaridis. (2006). Allogeneic stem cell transplantation as treatment for myelofibrosis. Bone Marrow Transplantation. 38(11). 721–727. 10 indexed citations
19.
Bloor, Adrian, María J. Sánchez, Anthony R. Green, & Berthold Göttgens. (2002). The Role of the Stem Cell Leukemia ( SCL ) Gene in Hematopoietic and Endothelial Lineage Specification. Journal of Hematotherapy & Stem Cell Research. 11(2). 195–206. 24 indexed citations
20.
Bloor, Adrian, et al.. (1998). Two cases of fatal bleomycin pneumonitis complicating the treatment of non-Hodgkin‘s lymphoma. Clinical & Laboratory Haematology. 20(2). 119–121. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Majid Kazmi Breakdown of academic impact, for papers by Manuela Badoglio Breakdown of academic impact, for papers by Massimo Degan Breakdown of academic impact, for papers by SC Jhanwar Breakdown of academic impact, for papers by RA Newman Breakdown of academic impact, for papers by HJ Sutherland Breakdown of academic impact, for papers by Jee Sook Hahn Breakdown of academic impact, for papers by Gianmaria Borleri Breakdown of academic impact, for papers by JE Leonard Breakdown of academic impact, for papers by Marie Parrens
Rankless by CCL
2026